Heat shock protein 90 inhibition: rationale and clinical potential

被引:46
作者
Den, Robert B. [2 ]
Lu, Bo [1 ]
机构
[1] Thomas Jefferson Univ, Jefferson Med Coll, Dept Radiat Oncol, Bodine Canc Ctr, Philadelphia, PA 19107 USA
[2] Thomas Jefferson Univ, Jefferson Med Coll, Dept Radiat Oncol, Philadelphia, PA 19107 USA
关键词
clinical trial; heat shock protein 90; pharmacological inhibition;
D O I
10.1177/1758834012445574
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Heat shock protein 90 (HSP90) is a molecular chaperone protein essential for cellular survival. Functionally, HSPs promote proper protein folding, prevent misfolding, and restore three-dimensional protein structure which is critical following toxic cellular stresses. Recently, targeting HSP90 pharmacologically has gained traction in cancer therapy. Oncogenic cells depend on their ability to withstand endogenous (anoxia, nutrient deprivation, pH changes, and deranged signaling pathways) and exogenous (chemotherapy and radiation therapy) stressors for survival. Pharmacological inhibition of HSP90 destabilizes proteins and leads to degradation through the proteasome. This article will review the utility of HSP90 inhibition, as well as the current adoption in clinical trials and practice.
引用
收藏
页码:211 / 218
页数:8
相关论文
共 55 条
  • [1] Phase I pharmacokinetic and pharmacodynarnic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies
    Banerji, U
    O'Donnell, A
    Scurr, M
    Pacey, S
    Stapleton, S
    Asad, Y
    Simmons, L
    Maloney, A
    Raynaud, F
    Campbell, M
    Walton, M
    Lakhani, S
    Kaye, S
    Workman, P
    Judson, I
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (18) : 4152 - 4161
  • [2] CUDC-305, a Novel Synthetic HSP90 Inhibitor with Unique Pharmacologic Properties for Cancer Therapy
    Bao, Rudi
    Lai, Cheng-Jung
    Qu, Hui
    Wang, Dagong
    Yin, Ling
    Zifcak, Brian
    Atoyan, Ruzanna
    Wang, Jing
    Samson, Maria
    Forrester, Jeffrey
    DellaRocca, Steven
    Xu, Guang-Xin
    Tao, Xu
    Zhai, Hai-Xiao
    Cai, Xiong
    Qian, Changgeng
    [J]. CLINICAL CANCER RESEARCH, 2009, 15 (12) : 4046 - 4057
  • [3] Divergent synthesis of a pochonin library targeting HSP90 and in vivo efficacy of an identified inhibitor
    Barluenga, Sofia
    Wang, Cuihua
    Fontaine, Jean-Gonzague
    Aouadi, Kaiss
    Beebe, Kristin
    Tsutsumi, Shinji
    Neckers, Len
    Winssinger, Nicolas
    [J]. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2008, 47 (23) : 4432 - 4435
  • [4] Re: Role of the heat shock response and molecular chaperones in oncogenesis and cell death
    Blagosklonny, MV
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (03) : 239 - 240
  • [5] Bonvini P, 2002, CANCER RES, V62, P1559
  • [6] Combining Hit Identification Strategies: Fragment-Based and in Silico Approaches to Orally Active 2-Aminothieno[2,3-d]pyrimidine Inhibitors of the Hsp90 Molecular Chaperone
    Brough, Paul A.
    Barril, Xavier
    Borgognoni, Jenifer
    Chene, Patrick
    Davies, Nicholas G. M.
    Davis, Ben
    Drysdale, Martin J.
    Dymock, Brian
    Eccles, Suzanne A.
    Garcia-Echeverria, Carlos
    Fromont, Christophe
    Hayes, Angela
    Hubbard, Roderick E.
    Jordan, Allan M.
    Jensen, Michael Rugaard
    Massey, Andrew
    Merrett, Angela
    Padfield, Antony
    Parsons, Rachel
    Radimerski, Thomas
    Raynaud, Florence I.
    Robertson, Alan
    Roughley, Stephen D.
    Schoepfer, Joseph
    Simmonite, Heather
    Sharp, Swee Y.
    Surgenor, Allan
    Valenti, Melanie
    Walls, Steven
    Webb, Paul
    Wood, Mike
    Workman, Paul
    Wright, Lisa
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (15) : 4794 - 4809
  • [7] SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers
    Chandarlapaty, Sarat
    Sawai, Ayana
    Ye, Qing
    Scott, Anisa
    Silinski, Melanie
    Huang, Ken
    Fadden, Pat
    Partdrige, Jeff
    Hall, Steven
    Steed, Paul
    Norton, Larry
    Rosen, Neal
    Solit, David B.
    [J]. CLINICAL CANCER RESEARCH, 2008, 14 (01) : 240 - 248
  • [8] ANALYSIS OF HEAT-SHOCK PROTEIN EXPRESSION IN MYELOID-LEUKEMIA CELLS BY FLOW-CYTOMETRY
    CHANT, ID
    ROSE, PE
    MORRIS, AG
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1995, 90 (01) : 163 - 168
  • [9] HEAT-SHOCK PROTEIN-HSP70 IN PATIENTS WITH AXILLARY LYMPH NODE-NEGATIVE BREAST-CANCER - PROGNOSTIC IMPLICATIONS
    CIOCCA, DR
    CLARK, GM
    TANDON, AK
    FUQUA, SAW
    WELCH, WJ
    MCGUIRE, WL
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (07) : 570 - 574
  • [10] Reaction of geldanamycin and C17-substituted analogues with glutathione: Product identifications and pharmacological implications
    Cysyk, RL
    Parker, RJ
    Barchi, JJ
    Steeg, PS
    Hartman, NR
    Strong, JA
    [J]. CHEMICAL RESEARCH IN TOXICOLOGY, 2006, 19 (03) : 376 - 381